Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What are you talking about???? This company has 2 clinical trials going, one in Phase 1 and one in Phase 2.
DD is a good thing.
Please explain....
PROT is a POS and done, stick a fork in it
I understand what you are saying, however, if it were really dead, would it not be in their interest to stop dragging this out, and let the chips fall where they may? By letting it go, they stay in the spotlight. Also, if the clinical trials are actually continuing, then who is funding it, and why?
Strongly agree groober. It least you are facing reality. This was a sham like so many pink sheets. Sorry to say I lost much more than 5K. I really got sucked in.
I'm sorry Rubs, but there really is nothing to go Bankrupt for. No assets, no capital, no facilities, no employees... It's a tax write off nothing more. While waiting for years for the trail to be complete, do not expect anything at all...Just stranded money and a big loss for many of us that funded this clinical trial. They porked us on the split and any potiential of getting any return. My $5K is gone and I accept it.
Does anyone know what happened to the payoff to Robert Kohn? And is ICEMAN still alive?
Rubs1 I hope you are right..
You would think that if there really was nothing going on here, the company would fold up its tent and declare BK. That is not happening, as they continue with clinical trials, which provides no financial value to the management team, unless they succeed. Therefore, I believe that if it was over, they would not be doing what they were doing, and just pull the plug. I think we have a reasonable chance to have this pulled out of the fire.
Funny - Patiently wait for an update in 2018? I think not. This was a pretty good gig for them though. Start a corporation, hire some scientists, create a drug, lay everyone off and sell the facility. Take the shareholdes money, lie about a spin off, take more money for the clinical trial for a family member that needs a cure.
Wow this could make a good book...
Thanks WM for the link and post :)
Estimated Enrollment: 30
Study Start Date: October 2013
Estimated Primary Completion Date: October 2018 (Final data collection date for primary outcome measure)
Also, here is a link to our phase 2 trial on the MD Anderson Cancer Center's website that contains an overview of the trial as well as its status which is open :)
http://utm-ext01a.mdacc.tmc.edu/dept/prot/clinicaltrialswp.nsf/Index/2012-0579
WM
Interesting....Proteonomix updated their Phase 2 trial on August 26, 2014. Most of you already know but for those of you that don't this trial is going on at the MD Anderson Cancer Center at the University of Texas which is one of the leading cancer research institutes in the US. Inserted below is a link to the trial as well as a link to the MD Anderson Cancer Center in case you were interested. Looks like they are hard at work behind the scenes and all we can do is patiently wait for an update.
Trial Link: https://clinicaltrials.gov/ct2/show/NCT01818284?term=proteonomix&rank=2
MD Anderson Cancer Center Link: http://www.mdanderson.org
WM
I just came across this article, and wondered where that money would be coming from.
http://www.law360.com/articles/515107/nj-biotech-co-can-t-dodge-former-cfo-s-exit-package
manxy, Where did you read or hear that there was a dividend issues? thx..
Yep it sure is. I still believe that patience is the factor here for the shareholders.
The fact that it is still traded is a positive factor.
manxy, have you any idea what's going on with this stock - or just here because you think i'm losing money? (btw, down a few pennies - except i own the spin-off for free)
company gave a dividend to anyone holding prot at close of last friday. one share for one share in a spin-off.
so people who think the spin-off (prot, ltd.) is the valuable prize, may have decided they don't want what's left (stromacel). some people may have said, i can sell stromacel - break even - and have prot,ltd. for free. not a bad investment strategy. but if you believe stromacel side is worth much more than .50, why sell? (unless you were one of the earliest sellers monday)
IMO, SMART MONEY WANTS BOTH - AND HAS BEEN BUYING STROMACEL SINCE STOCK BROKE .50 .
and u, if shorts thought this was junk, why would they be covering here? shorts are greedy. they always think the stock could go to zero. that's the only way they can double their money. there is far more upside.
I guess I did now after all....but what do I know
Sorry Bud. The SEC has bigger fish to fry. I lost thousands here. That's the world of pink sheet stocks. The majority of pinky's are junk with no money, no management, and no scruples. Such was PROT and Cohen. I know a few here hold on "hoping" for a miracle, but I've seen this rodeo. We are screwed.
Isn't there a regulatory agency we can file a complaint with? FINRA? SEC? I mean at this point who cares if it bankrupts the Company this investment is now a zero anyway. No one should get away with this kind of conduct.
No one here can answer that question because the company (Cohen) has always shown a real disdain for shareholders and feels no need to communicate with them. For those who continue to believe that no news is good news, I'm sorry for you. I really got sucked into this one. Complete loss.
What a shame, I was extremely fearful of this being a scam when our BVI shares never showed up. My question is, what happened to the "technology", which is an asset that belonged to PROT shareholders? It essentially was stolen since it never wound up in the new entity anyways.
I too am very unhappy with what is/isn't going on here. However, I have not thrown in the towel. If the company is no longer active, then I would have expected Mr Cohen to have dissolved the venture. Since this has not yet happened, there is still 'hope'.
Have to agree with you groober. If Cohen ever did stick his head up now the shareholder lawsuits would overwhelm him. There is no way out now. The liver trial must have been a bust; but of course we were never told. Even if MD Anderson finds value in the drug, Cohen has painted himself into a corner. There is a long list of shareholders that would join a class action lawsuit against him, and the company for the damage he has done.
I'm sorry, news really? I have no respect for a company that porks it's share holders and does not communicate anything for over a year. They took our money and ran. There is no company, no employees, no physical business. This one is dead and stinkin.
5 more months till 2015, Wonder if we will hear anything by then?
That is a good point rubs.
Your guess is as good as mine - anything is possible. We won't know until the company issues some sort of update.
WM
Do you think that maybe it had to be restarted when it got transferred to Rutgers? I hope that is the issue.
Inserted below is a hyperlink that takes you to the government site for clinical trials. As you will see, the trial that we are all interested in was supposed to be completed last September and hasn't been verified since January of 2013 (not very promising). However, their new trial at the M.D. Anderson Cancer Institute seems active as it was last verified and updated in May of 2014.
http://www.clinicaltrials.gov/ct2/results?term=proteonomix&Search=Search
Has anyone tried to find out if the clinical trials are still active, and when they are expected to be completed?
We have no alternative other than to wait and see what transpires.
You are correct that there are no employees, but what would that be needed for, the trials, I believe, are being run by the hospital, with no expense to us.
Some of us have no choice to wait... It's either going to go or die eventually. Remember there is no staff to this company, only Cohen these days, no physical address for a business any mor. Corporate mailing address is now a house. Absolutely no news from Cohen in well over a year now.... Just a hope and a prayer that the trails are successful.
Only a Dumb*ss would give up on a entity that has (2) drugs in Phase 1/2 trials with extremely high regarded medical facilities.....take the skirt off!
Took me for a ride from $1 to $7. Wish all "POS" stocks would do that.
Did not take me for anything, as I sold about half my holdings into last year's ride up to $6+. I did however, buy back some for a speculative flyer. It is not over yet. Prior to last year's run, the same things were being said. Patience Grasshopper.
And nothing since... POS took us for a ride !
Lots of activity today, including a 100,000 share trade at $0.04, followed by a lot of sells in the two-o'clock hour.
Spoke with the general council. Number listed on pinksheets.
Could give no info. I don't think these guys exist but here is the corporate wiki on them if anyone does care to do DD
http://www.corporationwiki.com/New-Jersey/West-Orange/stromacel-inc/35958103.aspx
IMO. I personally think that the trials are still going on. We know now that Rutgers UNv took over the Unv of medicine and dentistry. THe trial still shows as going on at http://www.clinicaltrials.gov/ct2/show?term=proteonomix&rank=1 . (As long as I see that up I have hope and confidence) I dont know how far that set them back, maybe 6 mon to a year?? I don't know but I'm willing to give them more time. Do we really even have a choice now. We have been here for 2+ years whats another 6 mos or so. My opinion we will hear something in 2014. I'm sure they had to reorganize with that huge takeover. UMDNJ and University Hospital also spent millions on consultants to help with their transitions. So this would be an daunting task to get everything back on track. I'm here till the FAT lady sings :)
All IMHO ~
I wish my loss was 5K. I'm deeper than that. The fact that the liver trials ended last year and we never heard a word I think tells us how that trial went. I think this is hopeless, but Cohen managed to lock us up with his bogus plan to issue shares in a new company and try Europe to get away from the SEC. I'd like to see the SEC get a hold of him now.
I'm sitting on well over $5K loss with this stock... Many of us have no option to wait this out. Clinical trials go on for years and if it does not pass and fails to do what intended, we are all out. There is no real business other than looking for a cure for a family memebers desease... The cosmetics portion -Proteoderm appears to be non existant, along with the other stem cell research. According to stats, Coehn make $316K per year as COE and we inturn make nothing...There is no "company" anymore with a physical address, lab or anything else.
Yes that would be a great step on this journey and would instill a lot of confidence :)
Hopefully we will get some confirmation that we actually are entitled to those new shares.
The information that the studies are continuing is positive news.
That is good to hear. Glad you at least had a conversation with him, even if it wasn't that forthcoming in which I wouldn't expect it to be as he is tight lipped being the attorney and all. Good to know they are alive, so to speak. lol
Also don't forget the MD Andersen trials. There should be a lot forthcoming in the next 6 months IMO.
Followers
|
53
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3720
|
Created
|
07/17/06
|
Type
|
Free
|
Moderators |
Company Information:
187 Mill Lane
Mountainside, NJ 07092
Phone: 973-544-6116
Fax: 973-833-0277
E-mail: info@proteonomix.com
CIK: 0001469559
1. Through our operating subsidiary, National Stem Cell, we have developed a catalog of intellectual properties and patent applications. These technologies are designed to work together in a synergistic fashion. Our initial focus in stem cell therapeutics is to achieve a leadership position in:
We need to test its technologies and therapies before commercialization.
We have identified stem cells in the human pancreas and have applied for patents for cell surface markers (the molecules present on the surface of each cell which define the cell on what receptors are present - a technique often used to associate cells with certain immune functions) for these pancreatic stem cells as well as methods for their isolation. Based on the fact that these cells are autologous (from same person) rather than from a non-related donor, we anticipate that the cells that we are able to isolate will substantially reduce rejection when transplanted into the liver of the same diabetic patient. The company is performing further research in this area with the University of Miami.
2. Through National Stem Cell, we have developed a patent-pending container device for cryopreservation of stem cells (the process where cells are preserved by cooling to low sub-zero temperatures) that we believe will provide significant improvements in viable cell recovery and contaminant protection, both in freezing and thawing stem cells, than is found with cryostorage containers currently in use.
3. Multiple cosmetic products have been developed. The products are based on our patents describing our Secreted Matrix TM technology. These products are in production and their launch is scheduled for the beginning of 2010.
4.Laboratory services are provided by our wholly owned, accredited and operating reproductive cell/tissue banking service (sperm, ova, ovarian tissue, testicular tissue and embryos). It is anticipated that our laboratory services will provide advanced technologies and procedures for the collection, laboratory testing, bio-genetic typing, processing and cryogenic storage of stem cells from both umbilical cord and peripheral blood. Umbilical cord blood stem cells and reproductive cells are processed and banked for both allogeneic (transfer from one person to another) and autologous (derived from and used by the same individual) therapeutic transplantation for a variety of medical disorders, including leukemia and lymphoma with stem cells and infertility with sperm cells. We have developed and implemented a unique, effective and comprehensive strategy for the marketing of our services and products on a national and international scale for applications in stem cell therapeutics together with cell-tissue laboratory services.
Management:
Steven Byle, Secretary |
Important Company Highlights:
Proteoderm, our latest product.
Recent News:
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=prot
News of particular importance:
November 11, 2011 @4:00 PM
Proteonomix, Inc. (PROT) Announces That Its Subsidiary Proteoderm, Inc. Has Received the Approval of Its Application for INCI...
Michael Cohen, President of the Company, stated: "The approval of the CIR and its issuance of an INCI name to our Matrix NC-138 is a significant and momentous occasion. We have now demonstrated that we are committed to develop and deliver to the market safe and innovative products. The issuance of the INCI name will allow the company to move forward with commercialization of our cosmeceutical product, Proteoderm NC-138 in the USA."
Proteoderm Inc. has developed a line of anti-aging skin care cosmetics based on its research with stem cell derivatives. We are the first company to use a matrix of proteins ("Matrix NC-138") originally discovered in non-embryonic stem cells, to harness the anti-aging potential in cosmeceutical products.
Mr. Cohen continued: "We anticipate that our efforts to market the product and partner up with other cosmetic manufacturers will be greatly enhanced by the issuance of an INCI name."
Based in Washington, D.C., the Personal Care Product Council ("PCPC") has funded the Cosmetic Ingredient Review ("CIR") Expert Panel as an independent, nonprofit panel of scientists and physicians established in 1976 to assess the safety of ingredients used in cosmetics in the U.S. with the support of the U.S. Food and Drug Administration and the Consumer Federation of America in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. The CIR mission is to review and assess the safety of ingredients used in cosmetics in an open, unbiased, and expert manner, and to publish the results in the peer-reviewed scientific literature. Upon conclusion of its review the CIR issues an International Nomenclature of Cosmetic Ingredients ("INCI") name to the ingredient. The PCPC does not regulate but provides information on national and international regulation. We presently adhere to the Personal Care Products Council Consumer Commitment Code, including filing timely reports with the FDA regarding manufacturing and ingredient usage.
Feb 18, 2010 08:30 ET
Proteonomix, Inc. (PROT) Announces the Formation of StromaCel, Inc.
Proteonomix, Inc. (PINKSHEETS: PROT) announces that it has formed a wholly-owned subsidiary, StromaCel, Inc.
The mission of StromaCel is to develop therapies using stromal cells. Stromal cells are key components of tissues and provide critical cytokines and growth factors as well as the cellular microenvironment for normal homeostasis. A cytokine is a small protein released by cells that affects the interactions and communications between cells and the behavior of cells. A growth factor is a naturally occurring substance capable of stimulating cellular growth, proliferation and differentiation. Homeostasis is a self-regulating process by which a biological system maintains stability while adjusting to changing conditions. Stromal cells provide a niche proliferation environment for stem cells.
StromaCel's goal is to study the basic cellular properties of stromal cells and to identify the utility of cellular and protein derivatives in disease repair.
StromaCel is the fifth subsidiary of Proteonomix. National Stem Cell, Inc. is Proteonomix' operating subsidiary. The Sperm Bank of New York, Inc., engaged in reproductive tissue banking, including sperm, ova, ovarian tissue and testicular tissue, is a subsidiary of National Stem Cell, Inc. Proteoderm has developed and has begun to manufacture and distribute a line of anti-aging cosmeceuticals based on stem cell derivatives. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Going forward, Proteonomix intends to create and dedicate a subsidiary to each of its technologies.
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteonomix has facilities at a number of academic institutions. Please visit www.proteonomix.com, www.proteoderm.com, www.pinksheets.com and www.sec.gov for further information about the Company.
Certain statements contained herein are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that the statements made in this press release relating to the mission statement of StromaCel constitute forward-looking statements and makes no guarantees of future performance and actual results or developments may differ materially from projections in forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the time the statements are made.
Filings:
Transfer Agent:
Olde Monmouth Stock Transfer Co., Inc.
200 Memorial Pkwy
Atlantic Highlands 07716
Share Structure:
Outstanding Common Shares
7,910,556 | a/o August 20, 2012 |
Float
5,155,665 as of Nov 4, 2011
Authorized Shares
240,000,000 as of Nov 4, 2011
Investor Relations:
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn't a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |